INNOVATIVE BIOTHERAPIES, INC.

Basic Information

650 AVIS DR # 300
ANN ARBOR, MI, 48108-9649

Company Profile

n/a

Additional Details

Field Value
DUNS: 143681240
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: 13


  1. Immunomodulatory Device for Treatment of Pediatric Acute Renal Failure Patients

    Amount: $364,723.00

    DESCRIPTION (provided by applicant): The Problem: The lack of devices specifically designed for pediatric applications has been recognized by directives in the Pediatric Medical Device Safety and Impr ...

    SBIR Phase I 2013 Department of Health and Human Services
  2. Selective Cytopheresis Therapy in Systemic Inflammatory Response Syndrome

    Amount: $1,432,240.00

    DESCRIPTION (provided by applicant): Leukocytes (LE) are major contributors to the pathogenesis and progression of many clinical inflammatory disorders, including the systemic inflammatory response sy ...

    SBIR Phase II 2012 Department of Health and Human Services
  3. Enhanced Propagation of Adult Human Renal Epithelial Cells Allowing for Commercia

    Amount: $1,990,126.00

    DESCRIPTION (provided by applicant): Renal cell therapy promises to improve the survival and overall health of patients suffering from acute renal failure (ARF), acute tubular necrosis (ATN), multiple ...

    SBIR Phase II 2010 Department of Health and Human Services
  4. Selective Cytopheresis Therapy in Systemic Inflammatory Response Syndrome

    Amount: $499,870.00

    DESCRIPTION (provided by applicant): An extracorporeal device, named selective cytopheretic device (SCD), has been fabricated that sequesters activated leukocytes and inhibits their release of inflamm ...

    SBIR Phase I 2008 Department of Health and Human Services
  5. Enhanced Propagation of Adult Human Renal Epithelial Cells

    Amount: $137,388.00

    DESCRIPTION (provided by applicant): Available therapies for renal failure continue to be suboptimal with associated mortality rates of over 50% for acute renal failure (ARF) and a life expectancy for ...

    SBIR Phase I 2008 Department of Health and Human Services
  6. Cell Therapy for Septic Shock

    Amount: $1,155,443.00

    DESCRIPTION (provided by applicant): Tissue engineering and cell therapy is a new and exciting approach to the treatment of acute and chronic diseases. The potential success of this therapeutic approa ...

    SBIR Phase II 2008 Department of Health and Human Services
  7. Renal Tubules for a Bioartificial Kidney: Monolayer Differentiation of ES Cells

    Amount: $249,999.00

    DESCRIPTION (provided by applicant): Over 400,000 people are currently being treated for End-Stage Renal Disease (ESRD) in the United States, with the number of patients expected to grow dramatically ...

    SBIR Phase I 2007 Department of Health and Human Services
  8. Cell Therapy for Septic Shock

    Amount: $500,000.00

    DESCRIPTION (provided by applicant): Tissue engineering and cell therapy are a new and exciting approach to the treatment of acute and chronic diseases. The potential success of this therapeutic appro ...

    SBIR Phase I 2006 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government